Bonness Enterprises Inc. maintained its stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,800 shares of the pharmaceutical company’s stock at the end of the second quarter. Bonness Enterprises Inc.’s holdings in GlaxoSmithKline PLC were worth $1,026,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after buying an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans raised its stake in GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock valued at $57,884,000 after buying an additional 1,371,490 shares during the period. Renaissance Technologies LLC raised its stake in GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock valued at $185,593,000 after buying an additional 1,316,600 shares during the period. Bank of America Corp DE raised its stake in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the period. Finally, Norges Bank bought a new stake in GlaxoSmithKline PLC during the fourth quarter valued at approximately $19,206,000. Hedge funds and other institutional investors own 8.98% of the company’s stock.
GlaxoSmithKline PLC (NYSE GSK) traded up 0.44% on Friday, hitting $40.93. The stock had a trading volume of 6,233,161 shares. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $45.58. The stock has a market cap of $100.03 billion, a P/E ratio of 40.36 and a beta of 1.04. The company’s 50-day moving average is $42.84 and its 200-day moving average is $41.78.
GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.84 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.80%. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 194.00%.
COPYRIGHT VIOLATION WARNING: “Bonness Enterprises Inc. Has $1,026,000 Position in GlaxoSmithKline PLC (NYSE:GSK)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/30/glaxosmithkline-plc-nysegsk-position-held-by-bonness-enterprises-inc-updated.html.
Several analysts have commented on GSK shares. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, April 5th. BNP Paribas upgraded GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and reduced their price objective for the stock from $45.58 to $37.20 in a research report on Wednesday, April 5th. Exane BNP Paribas upgraded GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a research report on Wednesday, April 5th. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. Finally, TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $46.00.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
